Finch Therapeutics Group Inc
NASDAQ:FNCH 1:50:30 PM EDT
| Market Cap (Intraday) | 24.72M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.50 |
| 50-Day MA | $0.64 |
| 200-Day MA | $1.77 |
Finch Therapeutics Group Inc Stock, NASDAQ:FNCH
200 Inner Belt Road, Suite 400, Somerville, Massachusetts 02143
United States of America
Phone: +1.617.229.6499
Number of Employees: 189
Description
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Somerville, MA.